Indikator likuiditas cepet Ensysce Biosciences (ENSC)

Ensysce Biosciences (ENSC) operates by developing abuse-deterrent analgesics, which ensures resilience against economic downturns and a lack of seasonality. Historical price action with the 0.61 indicator demonstrates the company's market context. High growth potential is driven by its patent portfolio, which will enable the scaling of global sales with low production costs following the completion of clinical trials.

The quick ratio measures a company's ability to instantaneously settle short-term obligations using only cash and accounts receivable, excluding inventory. By analyzing the quick ratio trajectory, an investor identifies the actual financial cushion stripped of illiquid assets. This metric discounts bankruptcy risk by confirming the business's solvency. For Ensysce Biosciences (ENSC), this is critical, as the high scalability of its intellectual property requires stable capital prior to the mass production stage.